Back نوفافاكس Arabic Novavax Catalan Novavax Czech Novavax German Novavax Greek Novavax Spanish Novavax Estonian نواوکس Persian Novavax French Novavax Hungarian
39°08′14″N 77°13′36″W / 39.1371°N 77.2267°W
 | |
| Company type | Public company |
|---|---|
| |
| ISIN | US6700024010 |
| Industry | Biotechnology |
| Founded | 1987[1] |
| Headquarters | , U.S. |
Area served | Worldwide |
Key people | |
| Products | Vaccines |
| Revenue |  US$983.7 million (2023)[2] |
Number of employees | 1,541[3] (2022) |
| Website | www |
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.[4]
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021,[5] and in Canada in February 2022,[6] as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca.
- ^ "Company Overview of Novavax, Inc". Bloomberg.com. Archived from the original on 24 February 2017. Retrieved 2 June 2019.
- ^ "Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights - Feb 28, 2024". ir.novavax.com. Retrieved 1 May 2024.
- ^ "Novavax Inc - Company Profile and News - Bloomberg Markets". Bloomberg.com.
- ^ Novavax Inc. 2020 Annual Report Archived 14 August 2021 at the Wayback Machine. Accessed 10 May 2021.
- ^ "EMA recommends Nuvaxovid for authorisation in the EU". European Medicines Agency (Press release). 20 December 2021. Retrieved 6 January 2022.
- ^ "Health Canada authorizes Novavax's Nuvaxovid COVID-19 vaccine". Health Canada, Government of Canada. 17 February 2022. Retrieved 21 February 2022.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search